Tandem Diabetes Care (NASDAQ:TNDM) Upgraded at Barclays

Posted by Geri Gentry on Oct 10th, 2026

Barclays upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM – Free Report) to a hold rating in a report issued on Wednesday morning,Zacks reports.

Several other research firms also recently commented on TNDM. Zacks Research downgraded Tandem Diabetes Care from a “strong-buy” rating to a “hold” rating in a report on Wednesday, June 10th. Royal Bank Of Canada reissued an “outperform” rating and issued a $26.00 target price (down from $30.00) on shares of Tandem Diabetes Care in a research note on Friday, August 7th. Canaccord Genuity Group set a $40.00 target price on shares of Tandem Diabetes Care in a report on Friday, August 7th. Oppenheimer reaffirmed an “outperform” rating on shares of Tandem Diabetes Care in a research report on Friday, August 7th. Finally, Mizuho cut their price target on shares of Tandem Diabetes Care from $24.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $27.18.

Read Our Latest Report on Tandem Diabetes Care

Tandem Diabetes Care Price Performance

Shares of NASDAQ TNDM opened at $16.11 on Wednesday. The company has a debt-to-equity ratio of 4.62, a current ratio of 3.18 and a quick ratio of 2.65. The business has a 50-day moving average of $19.34 and a 200-day moving average of $18.17. The stock has a market capitalization of $1.12 billion, a price-to-earnings ratio of -17.32 and a beta of 1.66. Tandem Diabetes Care has a fifty-two week low of $12.26 and a fifty-two week high of $29.65.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical device company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.01. The firm had revenue of $254.56 million during the quarter, compared to analysts’ expectations of $254.99 million. Tandem Diabetes Care had a negative return on equity of 45.97% and a negative net margin of 6.08%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.78) earnings per share. As a group, sell-side analysts predict that Tandem Diabetes Care will post -0.66 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. OP Asset Management Ltd bought a new stake in shares of Tandem Diabetes Care during the 1st quarter worth about $35,000. Integrated Wealth Concepts LLC acquired a new position in Tandem Diabetes Care in the 2nd quarter valued at about $33,000. Leonteq Securities AG raised its holdings in Tandem Diabetes Care by 21.7% in the 1st quarter. Leonteq Securities AG now owns 9,501 shares of the medical device company’s stock valued at $182,000 after acquiring an additional 1,695 shares during the period. Prosperitas Financial LLC bought a new position in Tandem Diabetes Care in the 2nd quarter valued at about $151,000. Finally, Pictet Asset Management Holding SA acquired a new stake in Tandem Diabetes Care during the first quarter worth approximately $206,000.

Tandem Diabetes Care Company Profile

(Get Free Report)

Tandem Diabetes Care, Inc is a medical device company focused on developing and commercializing advanced insulin delivery systems for people with diabetes. The company’s products are designed to work with continuous glucose monitoring (CGM) systems and digital health tools to help automate and personalize insulin therapy.

Tandem’s product portfolio includes the t:slim X2 insulin pump, which features a rechargeable design and software that supports automated insulin delivery. The company also offers the t:slim X2 pump with Control-IQ technology, an algorithm designed to adjust insulin delivery based on CGM readings, and the compact Tandem Mobi pump.